Novartis revealed this morning that it has decided to trim back its R&D pipeline by around 10% to 136 projects, as it continues its transition into a pure-play innovative medicines company. The shed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback